Biotechnology
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with Its Microarray Detection Platform
PathogenDx's Microarray Detection Platform is the fastest and most cost-effective test for UTI detection withhigher throughput for efficient and accurate diagnosis. SAN ANTONIO, Nov. 11, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the multiplexed urinary tract infection detection ind...
2024-11-11 23:00
1257
Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes
* Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day * 1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles[1] * People with dia...
2024-11-11 20:47
1350
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...
2024-11-11 20:30
1106
HKBN x INDICAID Introduce Hong Kong's First At-Home Health Test Monthly Subscription Service
HKBN further expands footprint in medical services HONG KONG, Nov. 11, 2024 /PRNewswire/ -- Hong Kong Broadband Network Limited ("HKBN") has partnered with renowned at-home health test brand, INDICAID, to provide HKBN customers with an innovative healthcare subscription service featuring a varie...
2024-11-11 16:06
1442
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading
biomarker company, announced that its CPa9-HNE biomarker assay received a
Letter of Support (LoS) from the U.S. Food and Drug Administration (FDA).
2024-11-11 15:00
1215
L'Oréal Showcases its Open Innovation Ecosystem Through Its Big Bang Beauty Tech Program at the 7th CIIE
Announcing North Asia BIG BANG Beauty Tech Innovation Program 2024 Winners and New Sustainability Track SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- L'Oréal has reaffirmed its unwavering commitment to open innovation through itsNorth Asia BIG BANG Beauty Tech Innovation Program (BIG BANG) at the 7th ...
2024-11-11 14:56
3809
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J., Nov. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia. This strategic expansion represents a significant m...
2024-11-11 10:58
1567
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
2024-11-11 08:07
1310
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity ofSaudi Arabia's prominent family business group...
2024-11-09 00:35
4249
Illumina signs MoU with PHASE to Advance Oncology Testing in the Greater Bay Area and Contribute to the ''Healthy China''
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Illumina Hong Kong LIMITED (Illumina), a global leader in DNA sequencing and array-based technologies, and PHASE Scientific International Limited (PHASE), aHong Kong-based biotech company with operations in the U.S. and the Greater Bay Area (GBA), signed a t...
2024-11-08 22:30
4219
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
2397
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
1485
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
1266
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-11-08 17:45
1137
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...
2024-11-08 16:30
1500
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...
2024-11-08 16:30
1744
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...
2024-11-08 11:27
1770
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN1...
2024-11-08 10:40
1416
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held inHouston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, ...
2024-11-08 08:20
1388
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk assessment. PLYMOUTH MEETING, Pa., Nov. 7, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network...
2024-11-07 21:37
1594
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 309 media titles]
2024-12-19 17:56
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 263 media titles]
2024-12-23 17:36
Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
10482
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
10090
